Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients

Future Oncology

Volumn 10, Issue 10, 2014, Pages 1751-1765

  Bock, Carolin ^a   Rack, Brigitte ^a   Huober, Jens ^b   Andergassen, Ulrich ^a   Jeschke, Udo ^a   Doisneau Sixou, Sophie ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

breast cancer; CD133; circulating tumor cells; EMT; N cadherin; stem cells

Indexed keywords

CD133 ANTIGEN; CELL MARKER; CYTOKERATIN; FLUORESCENT DYE; NERVE CELL ADHESION MOLECULE; CADHERIN; GLYCOPROTEIN; KERATIN; LEUKOCYTE ANTIGEN; PEPTIDE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST METASTASIS; CANCER PATIENT; CELL CULTURE; CELL SHAPE; CELL SIZE; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; EMBRYO; EPITHELIAL MESENCHYMAL TRANSITION; FLUORESCENCE; HUMAN; HUMAN CELL; MIDDLE AGED; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; STEM CELL; BREAST TUMOR; CANCER GRADING; CANCER STAGING; CANCER STEM CELL; COHORT ANALYSIS; FEMALE; GENE EXPRESSION; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; REPRODUCIBILITY; TUMOR CELL LINE; TUMOR EMBOLISM;

ADULT; AGED; ANTIGENS, CD; BREAST NEOPLASMS; CADHERINS; CELL LINE, TUMOR; COHORT STUDIES; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GLYCOPROTEINS; HUMANS; KERATINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; PEPTIDES; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84907923056     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.58     Document Type: Article

References (68)

1. Dontu G, El-Ashry D, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol. Metab. 15(5), 193-197 (2004).
2. Visvader JE. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev. 23(22), 2563-2577 (2009).
3. Mego M, Mani SA, Lee BN et al. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int. J. Cancer 130(4), 808-816 (2011).
4. Gao D, Vahdat LT, Wong S, Chang JC, Mittal V. Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res. 72(19), 4883-4889 (2012).
5. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119(6), 1420-1428 (2009).
6. Bednarz-Knoll N, Alix-PanabieRes. C, Pantel K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev. 31(3-4), 673-687 (2012).
7. Pinto CA, Widodo E, Waltham M, Thompson EW. Breast cancer stem cells and epithelial mesenchymal plasticity-implications for chemoresistance. Cancer Lett. 341(1), 56-62 (2013).
8. Mani SA, Guo W, Liao MJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4), 704-715 (2008).
9. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 3(8), e2888 (2008).
10. Wicha MS, Hayes DF. Circulating tumor cells: Not all detected cells are bad and not all bad cells are detected. J. Clin. Oncol. 29(12), 1508-1511 (2011).
11. Lianidou ES, Mavroudis D, Georgoulias V. Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. Br. J. Cancer 108(12), 2426-2432 (2013).
12. Stathopoulou A, Vlachonikolis I, Mavroudis D et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance. J. Clin. Oncol. 20(16), 3404-3412 (2002).
13. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351(8), 781-791 (2004).
14. Braun S, Vogl FD, Naume B et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353(8), 793-802 (2005).
15. Ignatiadis M, Georgoulias V, Mavroudis D. Micrometastatic disease in breast cancer: Clinical implications. Eur. J. Cancer 44(18), 2726-2736 (2008).
16. Pierga JY, Bidard FC, Mathiot C et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a Phase II randomized trial. Clin. Cancer Res. 14(21), 7004-7010 (2008).
17. Xenidis N, Ignatiadis M, Apostolaki S et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J. Clin. Oncol. 27(13), 2177-2184 (2009).
18. Rack B, Schindlbeck C, Andergassen U et al. Prognostic role of circulating tumor cells in the peripheral blood of breast cancer patients. Cancer Res. 24(Suppl. 2), Abstract S6-15, (2010).
19. Fehm T, Krawczyk N, Solomayer EF et al. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res. 10(5), R76 (2008).
20. Aktas B, Muller V, Tewes M et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol. Oncol. 122(2), 356-360 (2011).
21. Bonnomet A, Brysse A, Tachsidis A et al. Epithelial-To-mesenchymal transitions and circulating tumor cells. J. Mammary Gland Biol. Neoplasia 15(2), 261-273 (2010).
22. Hayes DF, Smerage JB. Circulating tumor cells. Prog. Mol. Biol. Transl. Sci 95, 95-112 (2010).
23. Alix-PanabieRes. C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. Annu. Rev. Med. 63, 199-215 (2012).
24. Bock C, Rack B, Kuhn C et al. Heterogeneity of ERalpha and ErbB2 status in cell lines and circulating tumor cells of metastatic breast cancer patients. Trans. Oncol. 5(6), 475-485 (2012).
25. Jordan NV, Johnson GL, Abell AN. Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer. Cell Cycle 10(17), 2865-2873 (2011).
26. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 11(4), R46 (2009).
27. Raimondi C, Gradilone A, Naso G et al. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res. Treat. 130(2), 449-455 (2011).
28. Armstrong AJ, Marengo MS, Oltean S et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol. Cancer Res. 9(8), 997-1007 (2011).
29. Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 13(3), R59 (2011).
30. Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res. 14(1), R15 (2012).
31. Rack B, Bock C, Andergassen U, Doisneau-Sixou S. Hormone receptor status, erbB2 expression and cancer stem cell characteristics of circulating tumor cells in breast cancer patients. Histol Histopathol. 27(7), 855-864 (2012).
32. Shipitsin M, Campbell LL, Argani P et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 11(3), 259-273 (2007).
33. Abraham BK, Fritz P, Mcclellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin. Cancer Res. 11(3), 1154-1159 (2005).
34. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5), 555-567 (2007).
35. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. Brca1 breast tumors contain distinct CD44+/ CD24-And CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 10(1), R10 (2008).
36. Vercauteren SM, Sutherland HJ. CD133 (AC133) expression on AML cells and progenitors. Cytotherapy 3(6), 449-459 (2001).
37. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100(7), 3983-3988 (2003).
38. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 432(7015), 396-401 (2004).
39. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65(23), 10946-10951 (2005).
40. Yin S, Li J, Hu C et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int. J. Cancer 120(7), 1444-1450 (2007).
41. Zhao P, Lu Y, Jiang X, Li X. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci. 102(5), 1107-1111 (2011).
42. Andrews JL, Kim AC, Hens JR. The role and function of cadherins in the mammary gland. Breast Cancer Res. 14(1), 203 (2012).
43. Fukata M, Kaibuchi K. Rho-family GTPases in cadherin-mediated cell-cell adhesion. Nat. Rev. Mol. Cell Biol. 2(12), 887-897 (2001).
44. Derycke LD, Bracke ME. N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int. J. Dev. Biol. 48(5-6), 463-476 (2004).
45. Fehm T, Becker S, Bachmann C et al. Detection of disseminated tumor cells in patients with gynecological cancers. Gynecol. Oncol. 103(3), 942-947 (2006).
46. Janni W, Hepp F, Strobl B et al. Patterns of disease recurrence influenced by hematogenous tumor cell dissemination in patients with cervical carcinoma of the uterus. Cancer 97(2), 405-411 (2003).
47. Krishnamurthy S, Cristofanilli M, Singh B et al. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer 116(14), 3330-3337 (2010).
48. Riethdorf S, Muller V, Zhang L et al. Detection and HER2 expression of circulating tumor cells: Prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin. Cancer Res. 16(9), 2634-2645 (2010).
49. Molloy TJ, Devriese LA, Helgason HH et al. A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. Br. J. Cancer 104(12), 1913-1919 (2011).
50. Barriere G, Riouallon A, Renaudie J, Tartary M, Rigaud M. Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis. BMC Cancer 12, 114 (2012).
51. Budd GT, Cristofanilli M, Ellis MJ et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12(21), 6403-6409 (2006).
52. Sieuwerts AM, Kraan J, Bolt J et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J. Natl Cancer Inst. 101(1), 61-66 (2009).
53. Bock C, Kuhn C, Ditsch N et al. Strong correlation between N-cadherin and CD133 in breast cancer: Role of both markers in metastatic events. J. Cancer Res. Clin. Oncol. doi:10.1007/s00432-014-1750-z (2014) (Epub ahead of print).
54. Kagan M, Howard D, Bendele T et al. A sample preparation and analysis system for identification of circulating tumor cells. J. Clin. Ligand Assay 25, 104-110 (2002).
55. Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10(20), 6897-6904 (2004).
56. Hong B, Zu Y. Detecting circulating tumor cells: Current challenges and new trends. Theranostics 3(6), 377-394 (2013).
57. Schwarzenbach H, Alix-PanabieRes. C, Muller I et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin. Cancer Res. 15(3), 1032-1038 (2009).
58. Coumans FA, Doggen CJ, Attard G, De Bono JS, Terstappen LW. All circulating EpCAM+CK+CD45-objects predict overall survival in castration-resistant prostate cancer. Ann. Oncol. 21(9), 1851-1857 (2010).
59. Rossi E, Basso U, Celadin R et al. M30 neoepitope expression in epithelial cancer: Quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin. Cancer Res. 16(21), 5233-5243 (2010).
60. Gong J, Jaiswal R, Mathys JM, Combes V, Grau GE, Bebawy M. Microparticles and their emerging role in cancer multidrug resistance. Cancer Treat. Rev. 38(3), 226-234 (2011).
61. Madhavan M, Srinivas P, Abraham E et al. Cadherins as predictive markers of nodal metastasis in breast cancer. Mod. Pathol. 14(5), 423-427 (2001).
62. Hou JM, Krebs MG, Lancashire L et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin. Oncol. 30(5), 525-532 (2012).
63. Vona G, Estepa L, Beroud C et al. Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology 39(3), 792-797 (2004).
64. Fehm T, Hoffmann O, Aktas B et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 11(4), R59 (2009).
65. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: Approaches to isolation and characterization. J. Cell Biol. 192(3), 373-382 (2011).
66. Pecot CV, Bischoff FZ, Mayer JA et al. A novel platform for detection of CK+ and CK-CTCs. Cancer Discov. 1(7), 580-586 (2011).
67. Balasubramanian P, Lang JC, Jatana KR et al. Multiparameter analysis, including EMT markers, on negatively enriched blood samples from patients with squamous cell carcinoma of the head and neck. PLoS ONE 7(7), e42048 (2012).
68. Lianidou ES, Markou A, Strati A. Molecular characterization of circulating tumor cells in breast cancer: Challenges and promises for individualized cancer treatment. Cancer Metastases Rev. 31(3-4), 663-671 (2012).